Interacting with Startups to Tackle Mental Healthcare
BioSpectrum Asia|BioSpectrum Asia Oct 2023
The Asia-Pacific Economic Cooperation APEC), a government organisation for economic cooperation across APAC countries, reported that mental illness accounted for more than 20 per cent of the total years lost and less than 50 per cent of the people affected by mental illness received evidence-based treatment. To address these mental health concerns, startups in the APAC region have new technologies for improving awareness of mental health, maintaining the privacy of a patient, improving accessibility, and reducing unwanted hospitalisation. There is also a rise in mental wellness solutions in the form of phone apps and other digital platforms which will enable a paradigm shift towards preventive mental healthcare in the next few years. Let’s delve further.
Interacting with Startups to Tackle Mental Healthcare

The Global Burden of Disease Study (GBD) published in 2019, revealed that mental diseases were among the top ten leading causes of global healthcare burden and this healthcare burden had not reduced since 1990. There are multiple reasons that led to mental health not being given due importance in terms of treatment as compared to physical health. They include stigma, lack of sufficient funding and policies, lack of workforce and no continuity in treatment, among others. It is further fueled by socio-economic gaps within each country and a lack of internet access and awareness.

Studies have reported that addressing mental health concerns has been critically low in low- and middle-income countries (LMICs). As LMICs account for over 50 per cent of the global mental health burden, it is crucial to increase public and private spending on evidence-based mental healthcare. Preventive healthcare strategies are also crucial to improve global mental wellness and may provide an effective method to reduce mental health-related risks and mortality.

Denne historien er fra BioSpectrum Asia Oct 2023-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra BioSpectrum Asia Oct 2023-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BIOSPECTRUM ASIASe alt
Inventia announces groundbreaking advancement in 3D cell culture technology
BioSpectrum Asia

Inventia announces groundbreaking advancement in 3D cell culture technology

Inventia Life Science, an innovator in 3D cell culture technologies, has announced the launch of RASTRUM Allegro, a groundbreaking advancement in 3D cell culture technology designed to accelerate drug discovery and disease research with unprecedented scalability, reproducibility, and efficiency.

time-read
1 min  |
March 2025
Aphra names Justin Untersteiner as CEO
BioSpectrum Asia

Aphra names Justin Untersteiner as CEO

The Australian Health Practitioner Regulation Agency (Ahpra) has appointed Justin Untersteiner as Chief Executive Officer (CEO).

time-read
1 min  |
March 2025
WHO partners with Siriraj Hospital in Thailand to address growing burden of injuries and falls
BioSpectrum Asia

WHO partners with Siriraj Hospital in Thailand to address growing burden of injuries and falls

The World Health Organization (WHO) has signed a Memorandum of Understanding (MoU) with Siriraj Hospital, Mahidol University, Thailand, to strengthen collaboration on trauma, injury, and fall prevention across the WHO South-East Asia Region to address the growing health, social, and economic challenges posed by these issues.

time-read
1 min  |
March 2025
Jubilant Biosys expands footprint in Europe for Biologics and Antibody Drug Conjugate services
BioSpectrum Asia

Jubilant Biosys expands footprint in Europe for Biologics and Antibody Drug Conjugate services

Jubilant Biosys Innovative Research Services Pte Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has executed the transaction definitive agreements with Pierre Fabre (PF) SA, and its affiliate entities, for JBIRSPL to acquire 80 per cent equity capital in JASMIN (new company incorporated by PF in France, as a Société par Actions Simplifiée (SAS)), with remaining 20 per cent retained by PF.

time-read
1 min  |
March 2025
PanopticAI gets US FDA clearance for contactless vital signs monitoring software
BioSpectrum Asia

PanopticAI gets US FDA clearance for contactless vital signs monitoring software

PanopticAI, a startup in remote patient monitoring space, has received 510(k) clearance from the US Food and Drug Administration (FDA) for its contactless vital signs monitoring software.

time-read
1 min  |
March 2025
Immuneel unveils India's first global CAR T-cell therapy for Non-Hodgkin's Lymphoma
BioSpectrum Asia

Immuneel unveils India's first global CAR T-cell therapy for Non-Hodgkin's Lymphoma

In a significant step forward for India’s cancer treatment, Immuneel Therapeutics has unveiled Qartemi, country’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a group of blood cancers.

time-read
1 min  |
March 2025
Axel Klarmeyer joins as CEO at Chamlion International
BioSpectrum Asia

Axel Klarmeyer joins as CEO at Chamlion International

China-based Chamlion, a pioneer in integrated dental 3D printing solutions, has announced the appointment of Axel Klarmeyer as the Chief Executive Officer (CEO) of Chamlion International, overseeing the company's international business operations.

time-read
1 min  |
March 2025
World Bank supports Bosnia and Herzegovina in strengthening healthcare
BioSpectrum Asia

World Bank supports Bosnia and Herzegovina in strengthening healthcare

The World Bank’s Board of Executive Directors has approved a $75 million Second Health Sectors Programmatic Development Policy Loan for Bosnia and Herzegovina (BiH).

time-read
1 min  |
March 2025
GHIT announces $12.7 M worth investment for developing diagnostics and drugs for malaria, NTDs
BioSpectrum Asia

GHIT announces $12.7 M worth investment for developing diagnostics and drugs for malaria, NTDs

The Global Health Innovative Technology (GHIT) Fund, headquartered in Japan, has announced a total investment of approximately JPY 2 billion ($12.7 million) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.

time-read
1 min  |
March 2025
NIH to lead implementation of National Plan to End Parkinson's Act in US
BioSpectrum Asia

NIH to lead implementation of National Plan to End Parkinson's Act in US

With support from the US Department of Health and Human Services (HHS) Office of the Assistant Secretary for Health (OASH), the National Institutes of Health (NIH) is leading the implementation of the Dr. Emmanuel Bilirakis and Jennifer Wexton National Plan to End Parkinson’s Act, which was signed into law on July 2, 2024.

time-read
1 min  |
March 2025